Mireia Puig-Campmany

Dr. Mireia Puig-Campmany

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1998 in JACC
Verified
Journal Article
Closed access
RLRubén Lamich
Rubén Lamich
MBManel Ballester
Manel Ballester
VMVicens Martí
Vicens Martí
VBVicens Brossa
Vicens Brossa
RARosa Aymat
Rosa Aymat
JNJagat Narula
Jagat Narula

23 February 2017 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
ABAna Juanes Borrego
Ana Juanes Borrego
NGNoé Garin
Noé Garin
MMMaria Antonia Mangues
Maria Antonia Mangues
SHSergio Herrera
Sergio Herrera
MPMireia Puig-Campmany
Mireia Puig-Campmany
MBMaria Isabel Baena
Maria Isabel Baena
Background The resolution of potential drug-related problems is a priority of pharmaceutical care programmes. Objectives To assess the clinical impact on drug-related negative outcomes of a pharmaceutical care programme focusing on the resolution of potential drug-related problems, initiated in the emergency department for patients with heart failure (HF) and/or chronic obstructive pulmonary disease (COPD). Methods Controlled trials, in which older adults (≥65 years) receiving four or more medications admitted to the emergency department for ≥12 hours for worsening of HF and/or COPD were randomised (1:1) to either a pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department (intervention group (IG)) or standard care (control group). Comparisons between the groups were made for the proportion of patients with drug-related negative outcomes, number of drug-related negative outcomes per patient, mean stay, patients readmitted within 180 days and 180-day mortality. Results 118 patients were included, 59 in each group. Fewer patients in the IG had drug-related negative outcomes (37 (62.7%) vs 47 (79.7%) in the control group (p=0.042)). Fewer drug-related negative outcomes per patient occurred in the IG (56 (0.95 per patient) vs 85 (1.44 per patient) in the control group (p=0.01)). The mean stay was similar between groups (194.7 hours in the IG vs 242.5 hours in the control group (p=0.186)). No difference in revisits within 180 days was found (32 (54.24%) in the IG vs 22 (37.3%) in the control group (p=0.065)). 180-Day mortality was detected in 11 (18.6%) patients in the IG compared with 13 (22%) in the control group (p=0.647). Conclusion A pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department has a favourable clinical impact, as it reduces the number and prevalence of drug-related negative outcomes. No difference was found in other outcome variables. Trial registration number NCT02368548.

15 November 2006 in Cerebrovascular Diseases
Verified
Journal Article
Closed access
JMJoan Marti-Fabregas
Joan Marti-Fabregas
YBYolanda Bravo
Yolanda Bravo
DCDolores Cocho
Dolores Cocho
JMJosep-Lluis Martí-Vilalta
Josep-Lluis Martí-Vilalta
JDJordi Díaz-Manera
Jordi Díaz-Manera
JMJosé Maestre
José Maestre
Background: To determine the frequency and predictors of symptomatic intracerebral hemorrhage (SICH) in patients treated with recombinant tissue plasminogen activator (rt-PA). Methods: We reviewed the databases of 7 tertiary hospitals that treated ischemic stroke patients with intravenous rt-PA. We recorded demographic data, vascular risk factors, time between onset and treatment, dose, the NIHSS score, body temperature, blood pressure, platelet count, blood glucose, antiplatelet treatment, and CT data. We also registered the study protocol used for treatment and deviations from the accepted protocol. A control CT was performed on all patients. SICH was diagnosed if a parenchymal hematoma was detected within the 36 h after rt-PA and was associated with an increase of ≧4 in the NIHSS score. Bivariate analyses were performed followed by a logistic regression analysis. Results: A total of 347 patients were studied, whose mean age was 68 ± 10.9 years; 56% were men. Thirty-two patients (9.2%) exhibited a parenchymal hematoma, and 8 patients (2.3%) suffered a SICH. Patients with SICH had a higher frequency of previous transient ischemic attack (p = 0.04), early signs of ischemia (p = 0.003), hyperdense arterial sign (p = 0.008), and deviations (p = 0.002). Early signs of ischemia (OR 8.5, 95% CI 1.6–45.4, p = 0.01) and deviation from the protocol (OR 11.1, 95% CI 2.4–50, p = 0.002) were independent predictors of SICH. Conclusions: SICH is infrequent in patients with ischemic stroke treated with rt-PA outside of a clinical trial. Its frequency increases in the presence of early signs of ischemia on the noncontrast CT scan and deviations from the recommended protocol.

1 March 2000 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
MPMireia Puig-Campmany
Mireia Puig-Campmany
MBManel Ballester
Manel Ballester
XMXavier Matías-Guiu
Xavier Matías-Guiu
RBRamón Bordes
Ramón Bordes
ICIgnasi Carrió
Ignasi Carrió
JNJagat Narula
Jagat Narula

1 March 2005 in Cerebrovascular Diseases
Verified
Journal Article
Closed access
RBRobert Belvís
Robert Belvís
JMJoan Marti-Fabregas
Joan Marti-Fabregas
DCDolores Cocho
Dolores Cocho
MGMaría Dolores García-Bargo
María Dolores García-Bargo
EFElisabeth Franquet
Elisabeth Franquet
JMJosep Lluis Martí-Vilalta
Josep Lluis Martí-Vilalta
Background and Objectives: To characterize the frequency, risk factors, clinical presentation and etiological subtypes of cerebrovascular diseases (CVD) following cardiac transplantation (CTX). Methods: In a retrospective review of our CTX database (period 1984–2002), we assessed demographic data, vascular risk factors, surgery and donor details. We classified ischemic stroke (IS) using the clinical criteria of the Oxfordshire Community Stroke Project and the etiological criteria of the TOAST study. Logistic regression analysis and survival curves were carried out. Results: CTX was performed in a total of 314 patients (age 46 ± 14 years, 78% male) and mean follow-up was 54 ± 57 months. Twenty-two patients (7%) presented CVD: hemorrhagic stroke in 12%, transient ischemic attack in 28% and IS in 60%. CVD were early postoperative (less than 2 weeks) in 20% of patients and late in 80%. The clinical presentation in patients with IS was total anterior circulation (23.1%), partial anterior (38.4%), lacunar (15.4%) and posterior circulation (23.1%), and the etiological classification was large artery atherosclerosis (15.4%), cardioembolism (14.4%), small vessel disease (15.4%), unusual causes (15.4%) and undetermined cause (38.4%). The only independent predictor of CVD was a prior CVD event with an odds ratio of 8.2 (95% CI, 2.2–30.2, p < 0.02). The estimated risk of CVD at 5 years was greater (p < 0.02) in patients with prior CVD (4.1%) than in those without (1.1%). Conclusions: CVD are a relatively frequent complication after CTX (7%) and usually occur in the late postoperative phase. CVD prior to transplantation increase the risk of CVD after this procedure.

1 September 2015 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
MRMiguel Alberto Rizzi
Miguel Alberto Rizzi
OBOlga H Torres Bonafonte
Olga H Torres Bonafonte
AAAitor Alquezar
Aitor Alquezar
SMSergio Herrera Mateo
Sergio Herrera Mateo
PSPascual Piñera Salmeron
Pascual Piñera Salmeron
DRDomingo Ruiz
Domingo Ruiz